There’s no escaping Mylan’s EpiPen these days, whether it’s congressional hearings looking into the drug’s dramatic price hike or the CEO’s $18 million salary. Adding to all this are two recent congressional letters that speculate that Mylan may not have been paying its fair share under the Medicaid drug rebate program.
House Energy and Commerce Republicans sent a letter to the HHS Office of Inspector General Sept. 12 calling for a review of CMS oversight of the Medicaid drug rebate program, specifically EpiPen’s drug classification under the program. Because EpiPen is classified as a generic, Mylan pays a 13 percent rebate, whereas it would pay a 23.1 percent rate if classified as a brand-name drug. Classifying EpiPen as a generic may have resulted in extra spending by state Medicaid programs, because Mylan paid a lower Medicaid rebate than it would have for a brand-name drug.
The House letter was followed by a nearly identical letter from Senate Republicans on the Finance Committee, and Linda Baumann, an attorney with Arent Fox, told me that it’s a serious problem when two congressional committees are concerned over CMS activities. Baumann said the letters are consistent with overall concerns over prescription drug price increases.
Medicaid spent $42.7 billion on generic and brand name drugs in fiscal year 2014, according to the Senate letter, and received $19.9 billion in rebates. The Senate letter included mention of a Sept. 8 memo from the National Association of Medicaid Directors that said that if EpiPen is considered a generic drug for the Medicaid rebate program, but is not a true generic, then it would be a case of taking advantage of the program.
Stay on top of new developments in health law and regulation with a free trial to the Health Law Resource Center.
Learn more about Bloomberg Law and sign up for a free trial.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to email@example.com.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to firstname.lastname@example.org.
Put me on standing order
Notify me when new releases are available (no standing order will be created)